From: Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan
Best response
N = 42
CR
1
PR
10
SD
22
PD
6
NE
3
ORR (%)
26.2
DCR (%)
78.5